USANA Health Sciences Reports First Quarter Net Sales of $248 Million and Diluted EPS of $0.95
SALT LAKE CITY--(BUSINESS WIRE)-- USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal first quarter ended April 1, 2023.
Key Financial & Operating Results
- First quarter net sales were $248 million versus $228 million for the fourth quarter of 2022 and $273 million during the first quarter of 2022.
- First quarter diluted EPS was $0.95 as compared with $0.66 for the fourth quarter of 2022 and $1.15 during the first quarter of 2022.
- Generated $13 million of operating cash flow during the quarter.
- Fiscal 2023 net sales and diluted EPS guidance updated to $875 to $950 million and $2.40 to $3.30, respectively, from $850 million to $950 million and $2.35 to $3.30.
Q1 2023 Financial Performance
|
Consolidated Results |
||
|
Net Sales |
$248 million |
|
|
Diluted EPS |
$0.95 |
|
|
Active Customers |
491,000 |
|
“USANA’s solid first quarter performance was driven by several initiatives that helped stabilize active customer counts and contribute to sequential quarter net sales growth,” said Kevin Guest, Chief Executive Officer and Chairman of the Board. “Our results during the first few weeks of the quarter benefitted from increased demand for several of our health products in China following the government’s shift in COVID policy. In addition, our announcement of product price increases in several markets stimulated product purchasing ahead of those increases. Because of the solid start to the year, we have raised the lower end of our net sales and earnings per share guidance.
“We continue to make progress on several key strategic initiatives for 2023, most of which are aimed at increasing the active customer base and positioning USANA for long-term sustainable growth. Key among these initiatives is the return to live sales meetings and events where possible. The in-person meetings and events held during and following the first quarter were targeted at engaging and further incenting our sales force and the feedback from these events has been encouraging. We remain optimistic that our overall strategy for the year will support customer engagement and stimulate positive momentum in our business.”
Q1 2023 Regional Results:
|
Asia Pacific Region |
||
|
Net Sales |
$200 million |
|
|
Active Customers |
386,000 |
|
|
Asia Pacific Sub-Regions |
||
|
Greater China |
||
|
Net Sales |
$124 million |
|
|
Active Customers |
242,000 |
|
|
North Asia |
||
|
Net Sales |
$30 million |
|
|
Active Customers |
54,000 |
|
|
Southeast Asia Pacific |
||
|
Net Sales |
$46 million |
|
|
Active Customers |
90,000 |
|
|
Americas and Europe Region |
||
|
Net Sales |
$49 million |
|
|
Active Customers |
105,000 |
|
“Our first quarter operating results were modestly ahead of expectations and were predominantly driven by increased customer activity in our Asia Pacific region. The operating leverage generated by the growth in revenue positively contributed to our first quarter operating performance,” said Doug Hekking, Chief Financial Officer.
Fiscal Year 2023 Outlook
The Company is raising the lower end of its net sales and earnings per share outlook for fiscal year 2023 as follows:
|
Fiscal Year 2023 Outlook |
||
|
|
Revised Range |
Previous Range |
|
Consolidated Net Sales |
$875 - $950 million |
$850 - $950 million |
|
Diluted EPS |
$2.40 - $3.30 |
$2.35 - $3.30 |
Mr. Hekking added, “We are raising the lower end of our guidance range for both net sales and earnings per share as a result of the performance in the first quarter. Sales during the first few weeks of the quarter benefited by approximately $12 million due to higher demand for several of our health products in China as well as an estimated $13 million in customer purchasing activity ahead of announced price increases. Furthermore, our fiscal 2023 outlook continues to reflect a wider range due to the continued uncertainty surrounding the operating and geopolitical environment around the world.”
Balance Sheet and Share Repurchase Activity
The Company generated $13 million of operating cash flow during the first quarter and ended the quarter with $295 million in cash and cash equivalents and remained debt-free. The Company did not repurchase shares during the quarter and, as of April 1, 2023, had approximately $83 million remaining under the current share repurchase authorization.
Management Commentary Document and Conference Call
For further information on the USANA’s operating results, please see the Management Commentary document, which has been posted on the Company’s website (http://ir.usana.com) under the Investor Relations section. USANA’s management team will hold a conference call and webcast to discuss today’s announcement with investors on Wednesday, April 26, 2023 at 11:00 AM Eastern Time. Investors may listen to the call by accessing USANA’s website at http://ir.usana.com. The call will consist of brief opening remarks by the Company’s management team, followed by a questions and answers session.
Non-GAAP Financial Measures
The Company prepares its financial statements using U.S. generally accepted accounting principles (“GAAP”). Constant currency net sales, earnings, EPS and other currency-related financial information (collectively, “Financial Results”) are non-GAAP financial measures that remove the impact of fluctuations in foreign-currency exchange rates (“FX”) and help facilitate period-to-period comparisons of the Company’s Financial Results that we believe provide investors an additional perspective on trends and underlying business results. Constant currency Financial Results are calculated by translating the current period's Financial Results at the same average exchange rates in effect during the applicable prior-year period and then comparing this amount to the prior-year period's Financial Results.
About USANA
USANA develops and manufactures high-quality nutritional supplements, functional foods and personal care products that are sold directly to Associates and Preferred Customers throughout the United States, Canada, Australia, New Zealand, Hong Kong, China, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Philippines, the Netherlands, the United Kingdom, Thailand, France, Belgium, Colombia, Indonesia, Germany, Spain, Romania, and Italy. More information on USANA can be found at www.usana.com.
Safe Harbor
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including: uncertainty related to the COVID-19 pandemic (“COVID-19”) to our business, operations and financial results; the potential for a resurgence of COVID-19 spread in any of our markets in the future; the impact of COVID-19 on the domestic and world economies, including any negative impact on discretionary spending, consumer demand, and consumer behavior in general; regulatory risk in China in connection with the health products and direct selling business models; regulatory risk in the United States in connection with the direct selling business model; potential negative effects of deteriorating foreign and/or trade relations between the United States and China; compliance with data privacy and security laws and regulations in our markets around the world; potential negative effects from geopolitical relations and conflicts, including the Russia-Ukraine conflict; potential negative effects of material breaches of our information technology systems to the extent we experience a material breach; material failures of our information technology systems; global economic conditions generally, including increasing inflationary pressure around the world and any negative impact on our operating costs, consumer demand and consumer behavior in general; reliance upon our network of independent Associates; risk associated with governmental regulation of our products, manufacturing and direct selling business model; adverse publicity risks globally; risks associated with our international expansion and operations; and uncertainty relating to the fluctuation in U.S. and other international currencies. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission. The forward-looking statements in this press release set forth our beliefs as of the date hereof. We do not undertake any obligation to update any forward-looking statement after the date hereof or to conform such statements to actual results or changes in the Company’s expectations, except as required by law.
| USANA Health Sciences, Inc. | ||||||
| Consolidated Statements of Operations | ||||||
| (In thousands, except per share data) | ||||||
| (Unaudited) | ||||||
| Quarter Ended | ||||||
| 1-Apr-23 | 2-Apr-22 | |||||
| Net sales |
$ |
248,360 |
$ |
272,867 |
||
| Cost of sales |
|
48,519 |
|
51,383 |
||
| Gross profit |
|
199,841 |
|
221,484 |
||
| Operating expenses: | ||||||
| Associate incentives |
|
106,070 |
|
119,620 |
||
| Selling, general and administrative |
|
66,926 |
|
68,797 |
||
| Earnings from operations |
|
26,845 |
|
33,067 |
||
| Other income (expense), net |
|
1,656 |
|
220 |
||
| Earnings before income taxes |
|
28,501 |
|
33,287 |
||
| Income taxes |
|
10,118 |
|
10,818 |
||
| NET EARNINGS |
$ |
18,383 |
$ |
22,469 |
||
| Earnings per share - diluted |
$ |
0.95 |
$ |
1.15 |
||
| Weighted average shares outstanding - diluted |
|
19,328 |
|
19,481 |
||
| USANA Health Sciences, Inc. | ||||||
| Consolidated Balance Sheets | ||||||
| (In thousands) | ||||||
| (Unaudited) | ||||||
| As of | As of | |||||
| 1-Apr-23 | 31-Dec-22 | |||||
| ASSETS | ||||||
| Current Assets | ||||||
| Cash and cash equivalents |
$ |
295,454 |
$ |
288,420 |
||
| Inventories |
|
64,490 |
|
67,089 |
||
| Prepaid expenses and other current assets |
|
35,934 |
|
28,873 |
||
| Total current assets |
|
395,878 |
|
384,382 |
||
| Property and equipment, net |
|
96,798 |
|
97,773 |
||
| Goodwill |
|
17,411 |
|
17,368 |
||
| Intangible assets, net |
|
31,971 |
|
32,432 |
||
| Deferred tax assets |
|
7,868 |
|
9,799 |
||
| Other assets |
|
55,607 |
|
54,795 |
||
| Total assets |
$ |
605,533 |
$ |
596,549 |
||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||
| Current Liabilities | ||||||
| Accounts payable |
$ |
10,511 |
$ |
11,049 |
||
| Other current liabilities |
|
119,711 |
|
132,784 |
||
| Total current liabilities |
|
130,222 |
|
143,833 |
||
| Deferred tax liabilities |
|
5,575 |
|
4,071 |
||
| Other long-term liabilities |
|
14,382 |
|
14,173 |
||
| Stockholders' equity |
|
455,354 |
|
434,472 |
||
| Total liabilities and stockholders' equity |
$ |
605,533 |
$ |
596,549 |
||
| USANA Health Sciences, Inc. | ||||||||||||||||||||
| Sales by Region | ||||||||||||||||||||
| (In thousands) | ||||||||||||||||||||
| (Unaudited) | ||||||||||||||||||||
| Quarter Ended | ||||||||||||||||||||
| April 1, 2023 | April 2, 2022 | Change from prior year | Currency impact on sales |
% change excluding currency impact |
||||||||||||||||
| Asia Pacific | ||||||||||||||||||||
| Greater China |
$ |
123,820 |
49.9% |
$ |
133,739 |
49.0% |
$ |
(9,919) |
(7.4%) |
$ |
(8,821) |
(0.8%) |
||||||||
| Southeast Asia Pacific |
|
46,286 |
18.6% |
|
54,742 |
20.0% |
|
(8,456) |
(15.4%) |
|
(2,125) |
(11.6%) |
||||||||
| North Asia |
|
29,608 |
11.9% |
|
29,939 |
11.0% |
|
(331) |
(1.1%) |
|
(1,690) |
4.5% |
||||||||
| Asia Pacific Total |
|
199,714 |
80.4% |
|
218,420 |
80.0% |
|
(18,706) |
(8.6%) |
|
(12,636) |
(2.8%) |
||||||||
| Americas and Europe |
|
48,646 |
19.6% |
|
54,447 |
20.0% |
|
(5,801) |
(10.7%) |
|
(635) |
(9.5%) |
||||||||
|
$ |
248,360 |
100.0% |
$ |
272,867 |
100.0% |
$ |
(24,507) |
(9.0%) |
$ |
(13,271) |
(4.1%) |
|||||||||
| Active Associates by Region(1) | ||||||||
| (Unaudited) | ||||||||
| As of | ||||||||
| April 1, 2023 | April 2, 2022 | |||||||
| Asia Pacific | ||||||||
| Greater China |
74,000 |
34.1% |
79,000 |
32.3% |
||||
| Southeast Asia Pacific |
61,000 |
28.1% |
76,000 |
31.0% |
||||
| North Asia |
35,000 |
16.1% |
36,000 |
14.7% |
||||
| Asia Pacific Total |
170,000 |
78.3% |
191,000 |
78.0% |
||||
| Americas and Europe |
47,000 |
21.7% |
54,000 |
22.0% |
||||
|
217,000 |
100.0% |
245,000 |
100.0% |
|||||
| Active Preferred Customers by Region (2) | ||||||||
| (Unaudited) | ||||||||
| As of | ||||||||
| April 1, 2023 | April 2, 2022 | |||||||
| Asia Pacific | ||||||||
| Greater China |
168,000 |
61.3% |
176,000 |
57.3% |
||||
| Southeast Asia Pacific |
29,000 |
10.6% |
34,000 |
11.1% |
||||
| North Asia |
19,000 |
6.9% |
21,000 |
6.8% |
||||
| Asia Pacific Total |
216,000 |
78.8% |
231,000 |
75.2% |
||||
| Americas and Europe |
58,000 |
21.2% |
76,000 |
24.8% |
||||
|
274,000 |
100.0% |
307,000 |
100.0% |
|||||
|
(1) |
Associates are independent distributors of our products who also purchase our products for their personal use. We only count as active those Associates who have purchased from us any time during the most recent three-month period, either for personal use or resale. | ||||||||||||
|
(2) |
Preferred Customers purchase our products strictly for their personal use and are not permitted to resell or to distribute the products. We only count as active those Preferred Customers who have purchased from us any time during the most recent three-month period. China utilizes a Preferred Customer program that has been implemented specifically for that market. | ||||||||||||
View source version on businesswire.com: https://www.businesswire.com/news/home/20230425005960/en/
Investor contact:
Andrew Masuda
Investor Relations
(801) 954-7201
investor.relations@usanainc.com
Media contact:
Dan Macuga
Public Relations
(801) 954-7280
Source: USANA Health Sciences, Inc.
Released April 25, 2023